Hormone-Balancing Effect Of Pre-Gelatinized Organic Maca (Lepidium Peruvianum Chacon): (III) Clinical Responses Of Early-postmenopausal Women To Maca In Double Blind, Randomized, Placebo-controlled, Crossover Configuration, Outpatient Study
|Values||(pg/ml) Placebo first: Placebo: 21.89 Maca: 16.22 SED: 2.44 Maca first: Placebo: 23.55 Maca: 24.11 SED: 2.39|
|Trial Design||Randomized trial|
|Trial Length||1-6 months|
|Number of Subjects||34|
In a randomized, double-blind, placebo-controlled crossover trial, 34 healthy, early postmenopausal women took 2 g of gelatinized maca or placebo for 2 months each.
Blood pressure wasn't different when on maca or placebo. Follicle-stimulating hormone was nonsignificantly lower while on maca than on placebo for the group that received placebo first, but not the group that received it second. Estradiol was significantly and considerably higher while on maca in the group that received placebo first, but not the group that received it second. Progesterone wasn't significantly different while on maca or placebo, and luteinizing hormone was significantly lower on maca than placebo in the group that received placebo first, but not the group that received maca first.
T3 was significantly lower while on maca than placebo in the group that received maca first, cortisol was significantly lower in the group that received placebo first, and adrenocorticotropic hormone was significantly lower in the group that received placebo first, but not their opposite crossover conditions. There was a significant increase in LDL in the group that received placebo first but no other statistically significant differences in lipid profile. Menopausal symptoms were significantly lower for both placebo and maca first on Kupperman's Menopausal Index, and only in the placebo-only group for Greene's Menopausal Score. The specific symptoms that saw significant reductions were hot flushes, sleep interruption, and nervousness.